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Abstract
Background: Recognizing patterns of coronary heart disease (CHD) risk in families helps to identify and target
individuals who may have the most to gain from preventive interventions. The overall goal of the study is to test
the effectiveness and sustainability of an integrated care model for managing cardiovascular risk in high risk
families. The proposed care model targets the structural and environmental conditions that predispose high risk
families to development of CHD through the following interventions: 1) screening for cardiovascular risk factors,
2) providing lifestyle interventions 3) providing a framework for linkage to appropriate primary health care facility,
and 4) active follow-up of intervention adherence.
Methods: Initially, a formative qualitative research component will gather information on understanding of diseases,
barriers to care, specific components of the intervention package and feedback on the intervention. Then a cluster
randomized controlled trial involving 740 families comprising 1480 participants will be conducted to determine
whether the package of interventions (integrated care model) is effective in reducing or preventing the progression of
CHD risk factors and risk factor clustering in families. The sustainability and scalability of this intervention will be
assessed through economic (cost-effectiveness analyses) and qualitative evaluation (process outcomes) to estimate
value and acceptability. Scalability is informed by cost-effectiveness and acceptability of the integrated cardiovascular
risk reduction approach.
Discussion: Knowledge generated from this trial has the potential to significantly affect new programmatic policy and
clinical guidelines that will lead to improvements in cardiovascular health in India.
Trial registration number: NCT02771873, registered in May 2016 (https://clinicaltrials.gov/ct2/show/results/
NCT02771873)
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Background
Coronary heart disease (CHD), now the leading cause of
death and disability [1], strikes mostly in the productive
mid-life years and at least a decade earlier in Indians in
comparison to their Caucasian counterparts [2–4]. A
positive family history (FH+) is well-recognised as a
consistent and independent risk factor for CHD [5] fea-
turing in several cardiovascular risk prediction scores
commonly used in clinical practice [6–9]. Additionally,
the FH+ of premature vascular disease was associated
with a greater lifetime risk of CHD mortality in a large
cohort of men (n = 49,255) with low risk factor burden
[10]. More importantly, the increased risk of cardiovas-
cular disease conferred by FH+ is mediated in large
part by modifiable risk factors and thus family history
is helpful in identifying individuals who may have the
most to gain from preventive interventions.
While FH+ can influence greater awareness of risk with
early and possibly more intensive risk factor modification
measures, it is unclear if these measures lead to reversal
of the increased risk associated with these individuals.
Current preventive management of individuals with FH+
of CHD is however ‘reactive’ based on development of risk
factors rather than ‘proactive’ global risk reduction mea-
sures of reducing total cardiovascular risk. In a recent
study, treated hypertensive individuals with a FH+ of
CHD reported better longitudinal reduction in blood pres-
sure (BP) and this is consistent with the recommendations
of intensive management of risk factors in individuals with
FH+ [11].
Lifestyle changes are likely to be more effective when
delivered to the whole family than to individuals as it works
within the framework of biologic and cultural relationships
to affect risk reduction. Family-based approaches that target
the whole family, encourage communication among the
family unit, and address the structural and environmental
conditions in which families live and operate, are consid-
ered to be effective approaches to promote cardiovascular
health [12]. Although cardiovascular risk factors cluster to-
gether in individuals, comprehensive interventions involv-
ing family members reduced the magnitude of risk factor
clustering in a worksite based demonstration project in
India [13, 14]. However, how cardiovascular interventions
can be developed in a culturally appropriate manner in
family settings has not been explored in detail in a sys-
tematic way. We propose to use mixed methods (quali-
tative research, randomized control trial (RCT), and
cost-effectiveness analysis) to integrate cardiovascular
risk reduction strategies in high risk families with FH+
of premature CHD and evaluate their effectiveness.
Methods
The major aims of the study are as follows: (1) to identify
barriers to implementing an integrated cardiovascular risk
management program in families of individuals with a
positive history of CHD, (2) to assess the effectiveness of
an integrated cardiovascular risk management strategy
(consisting of screening for risk factors, lifestyle education
and linkage to primary care for cardiovascular risk factor
management) on modifying risk factor clustering in fam-
ilies, and to assess changes in BP, lipids, glucose, haemo-
globin A1c (HbA1c), smoking, diet and physical activity
and (3) to estimate the scalability of the integrated cardio-
vascular risk reduction strategy in families of individuals
with a positive history CHD for state- or nation-wide
implementation.
The proposed project uses mixed methods to achieve
the study aims. The three design approaches include:
Aim 1, formative qualitative research; Aim 2, a random-
ized controlled trial; and Aim 3, cost effectiveness and
evaluative qualitative research to inform acceptability
and scalability.
Formative qualitative research (Aim 1)
Semi-structured focus group discussions (FGDs) of 6–12
adults with FH+ of CHD will gather information on un-
derstanding of diseases, barriers to care, and feedback
on the intervention (lifestyle education, care and linkage
coordination) (Table 1). Similarly, FGDs will be conducted
among other stakeholders such as frontline community
health workers (FCHW). Key informant interviews (n = 6)
will also be conducted among primary care physicians.
The qualitative approach will largely focus on recognising
solutions to previously identified potential barriers that
Table 1 Formative qualitative methods to inform cardiovascular risk management integration
Method Participants Number Topics
Focus
Groups
Individuals with family history
of AMI
-Males groups aged 18-40, 40+
-Female groups aged 18-40, 40+
-3 discussions in each gender-age category,
(12 total discussions)
-Each focus groups include 6-12 participants
• Family history as a risk factor for future cardiovascular
event.
• Perceptions and behaviours regarding other risk factors
of CHD
• Suggested intervention components and methods
• Gauge community interest in planned intervention
components
Frontline community health
workers
-4 focus groups
-Each focus groups include 6-12 participants
• Perceived patient barriers to lifestyle change, and an
integrated cardiovascular risk reduction initiative
• Gauge feasibility of planned intervention components
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may impede first-degree relatives from engaging in risk-
reducing behaviors [15] and they include: (1) failure to
understand the importance of family history as a risk fac-
tor for heart disease; (2) denial of a FH+, inappropriate
risk perception or underestimation of one’s own vulner-
ability; (3) failure of health workers to screen and provide
advice; and (4) inability to sustain risk-reducing behaviors
after implementation and poor control among those in
treatment. The intervention and trial protocols will be
then modified to incorporate key findings collected from
focus groups to make the intervention more contextually-
relevant.
Integrated cardiovascular risk reduction intervention
(Aim 2)
A randomized controlled trial of families of individuals
with a positive history of CHD will be used to address
Aim 2 (Fig. 1). Eligibility criteria: Eligible families will
include those with at least one family member with
physician confirmed CHD diagnosed before the age of
55 years. If there are family members who have died from
CHD (physician confirmed deaths) before the age of
55 years, such families will also be eligible to participate in
the study. The medical records of CHD patients will be
used to confirm the diagnosis and the age of the index case.
A written informed consent to the study randomization
plan from the head of the family will be a mandatory
eligibility criterion. All participating family members
will be required to provide individual consent to par-
ticipate. Family randomization: Each family will be ran-
domly assigned to participate in either the treatment
intervention arm (integrated CVD risk management) or
usual care arm (no interventions other than initial
screening). Computer generated random numbers gener-
ated by an independent member who is not involved in
the study will be used for randomization. Randomization
of a family will be performed only after collection of
complete baseline data. The outcome assessors and the
data manager will be blinded from the intervention assign-
ment. The data analysts will be provided with the inter-
vention assignment only after complete database lock.
Participant eligibility criteria: A minimum of two mem-
bers from each family will be included even if they reside
in separate houses. Potential participants must be more
than 18 years of age and either first degree blood relatives
or spouses of the index case. Bedridden and terminally ill
patients will be excluded from the study. The detailed
study flow chart is presented in Fig. 1. Follow-up period:
All participants will be followed-up for two years after
randomization. Study related measurements will be con-
ducted at baseline, one year and two year time-points. The
full study flow chart is presented in Fig. 2.
Data collection
A structured questionnaire will be administered by trained
staff to collect relevant data at baseline, one year and two
year time-points. The questionnaire includes assessments
of demographic and socio-economic variables, general
health status, diet pattern, physical activity, tobacco, and
alcohol consumption. The World Health Organization
(WHO) STEPS instrument for chronic risk factor surveil-
lance has been modified and adapted to capture local, con-
textual information [16]. Dietary data will be collected
using a semi-quantitative food frequency questionnaire on
food items that are relevant to chronic diseases and
adapted from an ongoing cluster randomized trial in India
Fig. 1 Schematic diagram of the randomized controlled trial. CHD = Coronary heart disease, CVD = Cardiovascular disease
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[17]. Additionally, all participants will undergo anthropo-
metric and BP measurements at three time points (base-
line, year 1 and year 2). Anthropometric measurements
include height (in cm), weight (in kg) and waist circum-
ference (in Inches). BP and pulse rate will be measured
using electronic BP monitors (OMRON HEM-7130-L)
at all three time-points. Three measurements will be
taken at the respective houses of the participants by
trained staff, two minutes apart and after allowing the
participant to relax for at least five minutes before start-
ing the measurement. Participants will be instructed not
to consume any beverages (coffee, tea or soft drinks) and
alcohol at least one hour before taking the measurements.
They will also be instructed to abstain from smoking.
In fasting stage, 5 ml of blood will be collected at three
time-points, centrifuged at source for serum and plasma
separation, and transported to the study laboratory. They
will be stored under −20 °C freezer. The following bio-
chemical analyses will be performed on the collected
blood samples: lipid profile (total cholesterol, LDL
cholesterol, HDL cholesterol and VLDL cholesterol),
fasting plasma glucose, and haemoglobin A1c (Table 2).
Abstinence from tobacco at year 1 and year 2 will be
validated by assessing urinary cotinine metabolites. Spot
urine samples are collected at year 1 and year 2 for this
purpose. The study laboratory is accredited by the Na-
tional Accreditation Board for testing and calibration of
Laboratories (NABL), India and also part of international
external quality assurance programs (EQAS) such as
EQAS of BIO-RAD.
Fig. 2 CONSORT flow diagram of the randomized controlled trial design. CHD = Coronary heart disease, FCHW = Frontline community
health worker
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Study outcomes
To address Aim 2, several clinical outcomes are assessed.
Primary outcome: proportions in each group achieving or
improving risk factor control status (BP < 140/90 mmHg,
fasting blood glucose (FPG) < 110 mg/dl, low-density
lipoprotein (LDL) < 100 mg/dl, abstinence from smoking/
tobacco use: at least 3 out of 4 risk factors). Secondary
outcomes: 1) between group difference in number of opti-
mal cardiovascular health indicators (BP < 120/80 mmHg,
TC < 200 mg/dl, FPG < 100 mg/dl, >150 min/week of
moderate intensity physical activity, BMI < 25 kg/m2,
never used tobacco or quit >6 months ago and a healthy
diet score) [18], 2) between group mean difference in main
risk factors (SBP, DBP, LDL, FPG, and HbA1c), 3) propor-
tions meeting >80% of recommended process measures
(smoking cessation, moderate or high intensity physical
activity, and <5 g per person/day salt consumption, >3
daily servings of fruits and vegetables, <2 table spoons/
cubes of free sugar), and 4) proportions achieving or
maintaining ten year Framingham cardiovascular disease
(CVD) risk score [19]/WHO CVD risk score [20] of
<10% or the INTERHEART non-laboratory based score
of <5 [21].
Study intervention overview
Usual care arm: The usual care arm will be screened for
CVD risk factors. Screening results plus one time educa-
tion regarding management of risk factors will be pro-
vided to all family members. Patients with hypertension,
diabetes and dyslipidemia in the control arm will be also
referred to a primary health care facility. Treatment arm:
The study intervention is designed to leverage the exist-
ing health care infrastructure available at the community
level. Trained FCHW will be visiting the families to pro-
mote lifestyle intervention strategies at least once in two
months during the intervention phase. The intervention
will consist of three phases: 1) screening and detection
of CVD risk factors, 2) lifestyle (nutritional/physical activ-
ity education and tobacco cessation) counselling 3) FCHW
assisted linkage to primary care and 4) active follow-up
through a mobile phone application.
Intervention Part 1. Screening for CVD risk factors
(CONTROL AND TREATMENT ARMS)
All eligible adults in the selected families who provide
written informed consent will undergo a screening pro-
cedure for CVD risk factors. The families will then be
randomized to either the treatment or control arm. At
the start of the intervention program, high risk patients
in the usual care arm will be referred to the existing pri-
mary care system for further management.
Intervention Part 2. Lifestyle Education (TREATMENT ARM)
Lifestyle education intervention: The lifestyle education
component of the treatment arm will include 9–12
nutritional/tobacco/physical activity consultations. All
study participants within the selected families in the
treatment arm will participate in the lifestyle educa-
tion component. Within 30 days of study enrolment,
all participants will complete culturally specific semi-
quantitative food frequency questionnaires (FFQ) and
tobacco use surveys. FCHW will receive training from
Table 2 Study measurements
Study parameters Method/Instrument
Blood pressure in mmHg Electronic BP monitor (OMRON HEM-7130-L). Instrument validated by International Protocol for
device validation O’Brien et al, (Working Group on Blood Pressure Monitoring of the European
Society of Hypertension)
Height in Cm Stadiometer (Seca 213)
Weight in meter Digital weighing scales (Seca HN286)
Wait circumference in inches Non elastic measuring tapes (Seca 201)
Plasma glucose in mg/dl Enzymatic Colorimetric Assay method (modified GOD-PAP method based on the work of Trinder, 1969)
Glycosylate Hb (HbA1c), % High Performance Liquid Chromatography (HPLC)
Cholesterol in mg/dl CHOD-PAP enzymatic. Enzymatic In vitro Calorimetric method (automated clinical chemistry
analyzer Roche/Hitachi 902)
Triglycerides in mg/dl Enzymatic Calorimetric test, GPO-PAP method
High density lipoprotein cholesterol (HDL)
in mg/dl
Direct measurement. Automated method for direct determination.
Low density lipoprotein cholesterol (LDL) Direct measurement. Homogeneous Enzymatic Assay for direct quantitative determination (automated
clinical chemistry analyzer Roche/Hitachi 902), for samples with triglycerides more than 400 mg/dl.
Very low density lipoprotein cholesterol (VLDL) Estimation using Friedewald and Fredrickson Formula, 1972
Nicotine metabolites screening in urine. Lateral flow chromatographic immunoassay for the detection of cotinine in human urine at the
cut-off concentration of 200 ng/ml.
mg/dl milligram/deci litre, Cm Centimetre, mmHg milli meters of mercury, nd ng/dl nano gram/deci litre
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study staff prior to study implementation. Recommended
diet modifications for participants will focus on maintain-
ing a healthy weight via redistribution/reduction of calories
(by avoiding fried foods and sugar-sweetened beverages),
increasing fiber and protein intake via wheat and sprouted
pulses, reducing glycaemic load by switching from refined
white rice and bread to whole wheat, increasing fruit and
vegetable consumption, and reducing salt and sugar intake.
Tobacco cessation and strategies to change sedentary be-
haviour will also be discussed in the nutritional/tobacco/
physical activity consultations. Current tobacco users will
complete culturally appropriate cessation action guides
that identify triggers and action steps to promote tobacco-
free behaviours. Strategies to improve physical activity
levels of all members of the family will be discussed at least
two times during the intervention phase. Family consulta-
tions will be repeated every two months to assess dietary,
physical activity and tobacco use changes. FCHW workers
will also conduct peer-support group education meetings
with groups of 10 participants/families once in two
months. Support group meetings will review diet modifica-
tion and tobacco cessation recommendations and highlight
peers’ strategies that have led to successful improvements
in diet. All individuals with elevated CVD risk factors will
be invited to participate in at least 3 such peer-led support
groups during the period of the trial.
Linkage to primary care system: All high risk patients
from the treatment arm will be linked to appropriate
primary care clinics with assistance from FCHWs.
FCHWs will assist high risk patients to identify primary
or secondary care facilities and help them schedule ini-
tial appointments. For 24 consecutive months following
initial screening and randomization, participants from
the intervention arm will receive quarterly phone inter-
views to measure primary care clinic utilization and to
assess CVD risk factor management activities (lipid ex-
aminations, smoking cessation programs, hypertension
control, glucose monitoring).
Materials for intervention
We will adapt previously developed strategies in similar
studies for development of the intervention materials
[17]. Initially, each component of the healthy lifestyle be-
haviour related to CVD risk reduction (diet, physical ac-
tivity, tobacco, alcohol and adherence to treatment) will
be broken down into performance objectives for the
family. Given the practical feasibility of implementation,
resource constraints and the local context, these compo-
nents will be prioritized. In the final step, key potential
change objectives and the corresponding intervention
options will be set at both the individual and family
level. To communicate the selected change objectives
clearly and concisely, we will develop different tools after
conducting several FGDs with the potential participants
and FCHWs. Based on their inputs, materials such as
pamphlets for the family, a hanging calendar to describe
the dietary priorities for cardiovascular health in the family
and an individual diary to set behavioural goals for each
month will be developed. These materials will undergo
translation into the local language and will be used during
FCHW training. They will ultimately serve as communica-
tion aids between the FCHW and family members.
Care coordination and follow-up
Each family in the treatment arm will be assigned a
FCHW. During the intervention phase, FCHW workers
will meet with study patients once in two months to as-
sess study progress and participation. In addition, ques-
tionnaire data collection and blood draws at home visits
after study months 12 and 24 will help to assess detailed
attributes of cardiovascular management (FPG, HbA1c,
BP, and LDL measures). A mobile phone SMS platform
will be used to enhance follow-up. Via SMS, patients will
receive study visit reminders and prompts to encourage
adherence to treatment and lifestyle goals.
Cost effectiveness and acceptability analyses (Aim 3)
The intervention costs will include the resource inputs
(e.g., personnel salaries, and materials) that are required
to deliver the intervention (in total and per participant).
Direct and indirect costs incurred by each family will be
estimated using questionnaires administered at study
visits 0, 12 and 24. Questionnaires will capture direct
medical costs, direct non-medical costs (travel), and in-
direct costs (missed work time, and lost productivity).
To estimate the cost-effectiveness (cost per one count
decrease in clustering of risk factors), the between trial
group difference in intervention delivery and patient dir-
ect costs will be divided by the between group difference
in clustering of risk factors or cardiovascular risk score:
[costs treatment arm – costs standard arm]/[ΣΔ Primary
outcome-Treatment arm] – [ΣΔ Primary outcome-usual
care arm]. Similarly, incremental cost utility ratio will
also be calculated using data from a 12 monthly health
utility assessment. Quality adjusted life years (QALY)
will be used as the measure of health utility. The accept-
ability of the interventions will be assessed through
qualitative research. Semi-structured FGDs (4-6 each in
men and women) and in-depth interviews with FCHW
(6 interviews) will be used to gauge the acceptability of
the interventions.
Trial sample size and power
The sample size estimates accounts for the expected de-
pendency of variables [22]. This family based RCT with
740 families (370 in each arm) of at least two participants
each (minimum of 1480 enrolled participants) and no more
than 15% loss to follow-up after 2 years will have 90%
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power to detect an estimated 10% difference in the pro-
portion of participants at 3 or more CHD risk factor
goals, the primary effectiveness endpoint of this trial
(55% in the intervention group as compared to the ex-
pected rate of 45% in the control group). The baseline
rate of the composite primary outcome in a large clus-
ter randomized trial in India [17] is used as the ex-
pected rate in the control group (data not published)
and the lower limit of 95% confidence interval of the
improvement in the same composite outcome in a
demonstration project in India [13] is used to estimate
the rate in the intervention group (data not published).
This is for a two sided test with an alpha of 0.05 and a
rho or intra-cluster correlation coefficient (ICC) of
0.20. The ICC of the composite primary outcome is
also estimated from the baseline data of the above
mentioned cluster randomized trial [17]. The power in
this study is more than 80% for all secondary endpoints
of interest including the change in risk scores.
Participating centres
The study will be conducted in Kerala with active support
from Sree Chitra Tirunal Institute of Medical Sciences and
Technology (SCTIMST) in Trivandrum in India. In total,
3716 patients with premature (<55 years) non-fatal acute
coronary syndrome were registered in this hospital in the
last ten years. The average number of cases per year in this
center is in the range of 300–500. Nearly 500 patients are
registered in the last one year alone. We will invite 740
such families in this trial and the recruitment will involve
both prospective cases as well as cases in the last 1 year.
The medical records will be used to confirm the diagnosis
of CHD and the eligibility criteria (Age < 55 years).
Data entry and data management
Trained and certified project staff will collect data using
study questionnaires. They will also be trained in collec-
tion of clinical data from health records and/or personal
information. The project staff under the supervision of a
post-doctoral fellow and the principal investigator will
complete data entry on a specially designed tablet com-
puter based data application. The data application has
been developed on My SQL 7.0 server. The application
will upload the data directly on a cloud server. The data
will be collated, cleaned, queries resolved and analysed
centrally. All entries in the tablet application will be
double checked by the post-doctoral fellow using a spe-
cially designed data review application. The application
also allows the user to send queries directly back to the
field staff for their review and action. Further, the ac-
curacy of data entry in randomly selected fields (10% of
the general fields and all anthropometric, BP, and bio-
chemistry data) will be checked independently by the
study principal investigator.
The study will collect various type of research data in-
cluding both quantitative and qualitative data. Data will be
generated from focus groups, in-depth semi-structured
interviews, medical records, questionnaires, clinical and
anthropometric measurements and blood biochemistry.
All data will be de-identified to ensure confidentiality
of information.
Long-term data storage: Upon completion of data col-
lection and entry, data packets will be created containing
the following: a final STATA data file; a read me file de-
scribing data collection, entry, auditing, and cleaning; a
data dictionary with detailed description of study variables,
and an annotated PDF of questionnaires and laboratory
data with variables and coding noted. De-identified study
data will be maintained indefinitely at the secured data
servers of the study sponsor. Periodically, the data will be
checked to ensure long-term integrity of the datasets. A
master list linking study identifiers with individuals will be
maintained for five years to allow the researchers to reach
individuals if needed to inform them of individual study
results that could impact their health. After five years the
linkage file will be destroyed. Three years after the com-
pletion of the study, study data (de-identified quantitative
data including survey and data from clinical records and
qualitative data comprising de-identified transcripts) for
all participants who consent to having their data made
public will be made available to other researchers. Infor-
mation on the study will be available on the website of the
sponsor as well as reported in scientific journals and at
scientific conferences. In addition, the study results will be
included in clinicaltrials.gov. Interested collaborators
can contact the study PI to discuss the possibility of data
usage.
Data analysis plan
All quantitative analyses (for Aim 2) will follow recom-
mended intention to treat guidelines for RCT. A generaliz-
ing estimating equations (GEE) framework for clustered
data [23] will be used to assess the statistical significance
of any observed intervention effect on the primary end-
point. In this analysis, the dependent variable will be the
indicator for whether the study participant is at three or
more CVD risk factor reduction goals at the end of 12 and
24 months follow-up period, minus the observed probabil-
ity of this endpoint in the absence of an intervention (rate
in control group). An exchangeable working correlation
matrix will be used to incorporate the clustering within
the families, with a log link and binomial variance speci-
fied. The exponentiated point and interval estimates from
the intercept of this model will quantify the intervention
effect. A similar GEE approach will be used to estimate
and test the significance of intervention effects on second-
ary endpoints. For continuous markers, such as SBP, FPG,
HbA1c and LDL, the within-participant difference will
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serve as the dependent variable in a GEE model as above,
with the identity link function and the distribution speci-
fied as normal. To assess the causal effect of the interven-
tion adjusted for bias due to non-adherence and loss to
follow up, marginal structural models will be fit, embed-
ded around the analysis approaches outlined above [24].
All qualitative data, including that collected for Aim 1
and Aim 3, will comprise the verbatim transcripts of the
audio recordings from all focus group discussions and
interviews. Audiotapes of focus group discussions/inter-
views will be transcribed, de-identified, and the tran-
scriptions audited for accuracy. Using ATLAS.ti software
to manage the data, analyses of the textual data will fol-
low the thematic analysis (e.g., for suggestions from pa-
tients and care givers for the intervention). Key themes
will be identified from the data (inductively) and from
the discussion guides (deductively), and these themes will
be compared using structured comparisons to identify
specific issues relevant to sub-groups of participants.
To compare the cost-utility of the intervention to
standard arm management, we propose to calculate an
incremental cost/utility ratio [net costs to net utility:
costs of intervention – costs of control/utility of inter-
vention – utility of control]. To calculate utility, we will
use 12-monthly health utility. The chosen measure of
utility will be the closest option to a global measure, the
quality adjusted life year (QALY], and is calculated as
the sum of mean survival time [life years] x utility scores
at 12 and 24 months [25]. Both 12 and 24-month costs
per QALY will be reported. If the intervention is success-
ful, the modeled long-term cost-utility of the intervention
and usual care will be compared using Markov Chain
Monte Carlo estimation techniques, controlling for age,
gender, and risk factor prevalence under different plausible
scenarios for how these may evolve over time [26].
Then it will be compared to reference points from the
literature – e.g., ceiling ratios for costs per QALY that
are less than three times gross domestic product (GDP)
per capita [27, 28] that are considered cost-effective
[29] (India’s 2013 GDP per capita was $3990; threshold:
≤$11,100 per QALY).
Ethical oversight
The participants will be informed about the study and
provided with a detailed information sheet. Trained study
staff appointed by the principal investigator will obtain
written informed consent from all study participants and
also from the head of the family. The study is approved by
the institutional review boards of the Public Health Foun-
dation of India and Sree Chitra Tirunal Institute for Med-
ical Sciences and Technology. The study protocol is
registered with the clinical trial registry clinicaltrials.gov
(NCT02771873). All changes in the trial protocol will be
informed to the institutional review boards.
Discussion
A positive FH+ of CHD increases the propensity to de-
velop future cardiovascular events. Targeted CVD preven-
tion activities is therefore an attractive strategy to delay or
prevent CVD onset in a relatively high risk and easy to
identify population of individuals with FH+ of CHD. In-
volving family in cardiovascular health promotion, en-
gaging FCHW as agents of change in imparting lifestyle
education and counselling at the family level, and harnes-
sing the potential of existing primary care infrastructure
for intermediate risk management are the novel strategies
of the proposed trial. The trial is also unique in many
other ways: (a) the unit of randomization is at the family
level, (b) the delivery of lifestyle interventions is at the
family level, and finally (c) the study incorporates several
existing theories of family process and functions in the
intervention development.
Our trial is dependent on the mutual interdependence
of the family system. Although the family is viewed as a
complex social system, the elements are interconnected,
and it is often viewed as a whole. The whole system to-
gether frequently interacts with the environment. This is
the basic tenet of the family systems theory [30]. The
trial also draws strengths from the postulate that a
change in an individual’s role can initiate a change in
other family members. A life-threatening event in one of
the family members in the form of CHD therefore acts
as reason for change in health behaviours in others if the
change is supported by the family as a whole system
with additional support from the external environment
(society). In the double ABCX model of family systems
[31], the event (A), the family’s resources (B), and the
family’s perception of the event (C) all play a part in de-
termining the family’s response to an emerging priority
or need (X). The FCHW in our trial utilises this oppor-
tunity and positively interacts with the family to make
healthy changes not only for the index case but also for
other members in the family. The Circumplex model
[32] suggests that family cohesion and communication
are also important for the development and sustenance
of healthy behaviors. We therefore give importance to
family counselling by FCHW in our trial to overcome
the challenge of poor communication within families to
achieve the set goals.
Diet, physical activity and tobacco are the three main
areas that we are targeting for changes within the family.
Family eating habits largely depend upon food avail-
ability and family food supply. Contextually relevant
previous studies elaborate household dynamics of food
decision-making process and highlight the role of women,
children and cost considerations in arriving at a decision
[33]. In our study we therefore introduce healthier al-
ternatives of the existing common recipes, without ac-
tually changing the food items being prepared, to the
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homemakers and women in the family. The FCHW dis-
cuss these options with them during their routine visits
to the family. They also involve children in the family
and make them aware of the importance of healthy
diet. In our initial qualitative work, we find that the
time spent on cooking has declined over time in most
of the families due to increased use of moderately proc-
essed food or food brought from outside restaurants.
Our strategy is also to discourage the use of processed
food and food brought from outside as they are gener-
ally high in fat, sugar, and sodium.
We also take into account the cultural contexts within
the study settings. Snacking and hot beverages (tea/coffee)
use are almost universal in most of the families in these
settings. We provide suggestions for healthier alternatives
for family snacking and encourage family members to re-
duce the number of cubes/tea spoons of free sugar added
to their beverages or snacking items. Similarly, we instruct
them to quantify the use of salt, oil and sugar in cooking
and to take a cautious effort in reducing the overall
quantity of each of these items used within the family.
Additionally, culturally relevant options to improve the
overall physical activity levels of all members of the
family are discussed during the home visits by the
FCHW. All discussions are aided by simple and easy to
read hand-outs with pictorial representation of the key
messages to be conveyed to the family. Specially de-
signed individual diaries are given to all participants in
the intervention families to set monthly goals of desir-
able lifestyle changes. They are also used for tracking
individual changes in behaviours on a monthly basis.
The FCHW review these diaries once every two months
and give feedback to the participants.
In order to make our intervention approach more
comprehensive, we have introduced peer support groups
for risk reduction in individuals with established risk fac-
tors such as diabetes and hypertension or those who are
tobacco users. FCHWs organize these peer sessions with
the objective to aid behavioural changes that requires
support from outside the family.
The FCHWs in our study are trained to facilitate the
creation of a family environment that is conducive to
cardiovascular health. They are entrusted with the tasks
of modifying the family environment to promote the
adoption and sustenance of healthy behaviors, modeling
appropriate life-style behaviors, and encouraging self-
efficacy of the family to adopt and sustain new strategies
for overall improvement in cardiovascular health. The
FCHWs in India are known by many names such as
community health workers (CHW), community health
representatives (CHR), anganwadi workers (AWW),
junior public health nurses (JPHN), health visitors,
health inspectors, and accredited social health activists
(ASHA). We largely involve ASHA workers in our study.
Traditionally, FCHWs are involved in activities related to
maternal and child health and infectious disease manage-
ment. We train them as community agents to improve
cardiovascular health in families. In the era of a rapidly
progressing epidemiological transition in India, task shift-
ing/task sharing strategies such as involving FCHWs in
non-communicable disease prevention and control are
practical, feasible and scalable strategies. Such strategies
have been demonstrated to be cost-effective in low and
middle income settings [34]. Our study will also provide
evidence to support the task shifting/task sharing strategy
of involving FCHWs in prevention and control of cardio-
vascular disease. Even though the family has always been
central to effective intervention by FCHWs, their role in
nurturing a family in the perspective of total cardiovascu-
lar health is new to the field.
Despite improvements in individual risk factors in
multiple risk factor intervention trials, its effectiveness
on combined cardiovascular events and mortality are yet
to be established [35]. In order to establish the effect of
these interventions on cardiovascular morbidity and mor-
tality, large, multi-centric strategic trials are necessary.
Given that the power of such studies largely depend on
the number of outcome events observed during the study
period, they often require a longer follow-up period. Our
present study with the median follow-up of just two years
is not powered to detect changes in CVD morbidity and
mortality. Family based approaches that target both the
structural and environmental conditions in which a family
lives, and address possible barriers and facilitators of
adopting a healthy lifestyle need to be also evaluated for
their effectiveness to reduce cardiovascular events and
mortality in future.
Implications
The role of intensive lifestyle management at the family
level along with linkage to appropriate primary care for
cardiovascular risk management have not been explored
before. Knowledge generated from this trial has the po-
tential to significantly affect new programmatic policy
and clinical guidelines that will lead to improvements
in cardiovascular health in India and other low and
middle-income countries. The proposed trial will pro-
vide key results that address both feasibility and inter-
vention effect of integrated care. The implementable
results will address a disease that causes great morbid-
ity and mortality in low- and middle-income countries.
From a clinical perspective, little is known about the
natural history of cardiovascular risk factors in individ-
uals with positive FH+ of premature CHD. This trial
will importantly document the trajectories of BP, blood
glucose and blood lipids and determine if the existing
primary care infrastructure can be harnessed to im-
prove cardiovascular risk management.
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